Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
6.91
Nov 18 • 3:59 PM ET Dollar change-0.17 Percentage change(-2.40%)
Aftermarket Close
6.91
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Index
-
Market Cap
253.11M
Enterprise Value
227.13M
Income
-32.49M
Sales
23.63M
Book/sh
1.16
Cash/sh
0.91
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
162
IPO
Jun 09, 2016
P/E
-
Forward P/E
-
PEG
-
P/S
10.71
P/B
5.95
P/C
7.59
P/FCF
-
EV/EBITDA
-
EV/Sales
9.61
Quick Ratio
3.70
Current Ratio
4.54
Debt/Eq
0.17
LT Debt/Eq
0.06
Option/Short
Yes / Yes
EPS (ttm)
-0.93
EPS next Y
-0.65
EPS next Q
-0.26
EPS this Y
36.17%
EPS next Y
27.78%
EPS next 5Y
61.57%
EPS past 3/5Y
-0.76% -2.41%
Sales past 3/5Y
34.06% 17.12%
EPS Y/Y TTM
30.10%
Sales Y/Y TTM
65.25%
EPS Q/Q
20.30%
Sales Q/Q
85.86%
Insider Own
3.05%
Insider Trans
0.00%
Inst Own
45.08%
Inst Trans
0.01%
ROA
-64.68%
ROE
-87.04%
ROIC
-71.79%
Gross Margin
73.86%
Oper. Margin
-145.08%
Profit Margin
-137.51%
SMA20
2.56%
SMA50
9.25%
SMA200
4.10%
Trades
Shs Outstand
36.63M
Shs Float
35.51M
52W High
8.95 -22.79%
52W Low
4.80 43.96%
Volatility
6.10% 6.99%
ATR (14)
0.46
RSI (14)
51.94
Beta
0.73
Rel Volume
0.38
Avg Volume
208.56K
Volume
79,735
Perf Week
-11.97%
Perf Month
16.72%
Perf Quarter
3.91%
Perf Half Y
-0.14%
Perf YTD
-12.20%
Perf Year
10.91%
Perf 3Y
-35.18%
Perf 5Y
-42.13%
Perf 10Y
-6.66%
Prev Close
7.08
Price
6.91
Change %
-2.40%
Consensus
Strong Buy
Avg. Price Target
$11.28
Implied Upside
+63.2%
Analysts4incl. previous ratings
Rating Distribution3 Buy · 1 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jul 27, 2026Upgrade
RJF logoRRaymond James
Outperform → Strong Buy$11+59.2%
Jul 23, 2024Initiated
LLake Street
Buy$16.50+138.8%
Jul 16, 2024Upgrade
SF logoSStifel
Hold → Buy$9 → $12+73.7%
Nov 28, 2023Initiated
SF logoSStifel
Hold$11+59.2%
Aug 04, 2023Downgrade
RJF logoRRaymond James
Strong Buy → Outperform$20 → $200+2,794.4%
Mar 21, 2023Downgrade
JEF logoJJefferies
Buy → Hold$5.50 → $10+44.7%
Sep 15, 2020Initiated
JEF logoJJefferies
Buy
Profound Medical Corp. is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the ablation of diseased tissue utilizing its platform technologies. The firm's product, the TULSA-PRO system, combines real-time MRI, robotically driven transurethral sweeping action/thermal ultrasound, and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It is also focused on developing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. The company was founded on June 13, 2008 and is headquartered in Mississauga, Canada.
Ph.D.Dr. Arun Swarup Menawat MBA
Chief Technology OfficerDr. Mathieu Burtnyk Ph.D.
Chief Commercial OfficerMr. Thomas Tamberrino MBA
PresidentMr. Richard R. Fabian
CPAMr. Matthew Sobczyk C.A.